Streetbeat News

Stock Prices

FNV

Franco-Nevada (NYSE:FNV) has outperformed the market over the past 15 years, producing an average annual return of 15.2%. If an investor had bought $100 of FNV stock 15 years ago, it would be worth $797.98 today. The company currently has a market capitalization of $27.11 billion.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 8:30 pm

ADEA

NVDA

Adeia and NVIDIA have resolved their ongoing litigation on confidential terms, leading to a rise in Adeia's share prices.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:25 pm

ORCL

Oracle Corp (NASDAQ:ORCL) reported Q1 revenue of $12.45 billion, up 9% YoY, beating the Street consensus estimate. Adjusted earnings per share were $1.19, also beating estimates. Cloud revenue was $4.6 billion, up 30% YoY, with Cloud Application revenue at $3.1 billion (up 17% YoY) and Cloud Infrastructure revenue at $1.5 billion (up 66% YoY). Free cash flow was $5.7 billion, up 21% YoY. Oracle Cloud Services and License Support revenue now make up 77% of the company’s total revenue.

Portfolio Pulse from Chris Katje

September 11, 2023 | 8:25 pm

APRN

Blue Apron has announced that it will be transferring its stock listing from the New York Stock Exchange to Nasdaq. The ticker symbol will remain 'APRN'.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:21 pm

INTC

Intel Corporation's stock has been trending higher despite recent threats from China to semiconductor and tech stocks. The stock gained last week even as the sector weakened due to China's plans to restrict iPhone usage and Huawei's announcement of a new smartphone. Intel's presentation at the Citi Global Technology Conference was viewed positively by Citi analyst Christopher Danely.

Portfolio Pulse from Ryan Gustafson

September 11, 2023 | 8:20 pm

SGHT

Sight Sciences has issued Q3 total revenue guidance below estimates and also cut its FY23 revenue guidance below estimates. This has led to a decrease in the company's share price.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:18 pm

ABUS

Arbutus Biopharma Corporation has announced that it will discontinue all its coronavirus and oral RNA destabilizer programs, including AB-343 and AB-161. The company expects these pipeline changes to extend its cash runway through Q3 2025.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:17 pm

LRCX

A significant bearish stance has been taken on Lam Research (NASDAQ:LRCX) as indicated by unusual options activity. The overall sentiment of these big-money traders is split between 19% bullish and 80% bearish. Whales have been targeting a price range from $450.0 to $750.0 for Lam Research over the last 3 months. Stifel has maintained their Buy rating on Lam Research, with a price target of $750.

Portfolio Pulse from Benzinga Insights

September 11, 2023 | 8:16 pm

ORCL

Oracle reported mixed Q1 financial results, leading to a decrease in its share price.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:14 pm

CLDI

First Light Acquisition Group has announced that its business combination transaction with Calidi Biotherapeutics has been approved for listing on the NYSE. The transaction, expected to be completed on September 12, 2023, will provide Calidi with approximately $28 million in gross proceeds. Additionally, Calidi has secured a forward purchase agreement for up to $10 million with a consortium including Meteora Capital LLC, Great Point Capital LLC, and Funicular Funds, LP. The listed company will be named Calidi Biotherapeutics, Inc. and will trade under the ticker symbols 'CLDI' and 'CLDI WS'.

Portfolio Pulse from Benzinga Newsdesk

September 11, 2023 | 8:13 pm